IHC-P: Use at an assay dependent dilution. IP: Use at an assay dependent dilution. WB: Use at an assay dependent dilution. Detects a band of approximately 27 kDa (predicted molecular weight: 22 kDa). Optimal dilutions/concentrations should be determined by the end user.
Jurkat, HeLa, NIH/3T3, and KNRK
Reacts with p27 (also designated Kip1 p27)
PBS containing 0.1 % sodium azide and 0.2% gelatin
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
0.2 mg/ml (Please refer to the vial label for the specific concentration.)
Synthetic peptide corresponding to C terminal of Human p27.
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Cyclin Dependent Kinase Inhibitor 1B,Cdkn4,Kip1,Men1B,Men4,P27Kip1,Cdkn1B
Nuclear and cytoplasmic in quiescent cells
Cell cycle progression is regulated by cyclins and their cognate Cdks. p27 KIP 1 is a cell cycle regulatory mitotic inhibitor of cdk activity. p27 KIP 1 is a candidate tumor suppressor gene, and has been proposed to function as a possible mediator of TGF beta induced G1 arrest. p27 KIP 1 is up-regulated in response to antimitogenic stimuli. The increased protein expression of p27 results in cellular arrest by binding to cyclin/Cdk complexes such as cyclin D1/Cdk4. p27 Kip1 is regulated by phosphorylation on serine 10 (S10) and threonine 187 (T187). Phosphorylation by CDK2 on T187 results in ubiquitylation and degradation of p27 Kip 1; while phosphorylation by hKIS on S10 signals the nuclear export to the cytoplasm.